Smokescreen Translational (TL) Analysis Platform

Investigators are developing a predictive genomic test to personalize smoking cessation treatment.

Tobacco-attributable disease remains the largest potentially modifiable cause of mortality. Strategies to reduce smoking prevalence include developing more effective smoking cessation treatments. Using clinical and genomic data, investigators will develop prediction models of nicotine metabolism, nicotine dependence, and smoking cessation.

The investigators have previously designed Smokescreen®GTA, a genome-wide array that deeply captures variation in over 1,000 addiction genes, including the most important loci for nicotine metabolism and nicotine dependence. Prior research has identified multiple metabolic and regulatory genes, that with relatively few markers, can predict an individual’s nicotine metabolic activity.

In this study, researchers will develop a compact laboratory assay for genotyping DNA samples with specific markers and software to analyze clinical and genomic data (Smokescreen®TL).

Smokescreen®TL will be validated in smokers in clinical care. Ultimately, Smokescreen®TL will be available for use by health care providers interested in helping treatment seeking smokers quit.

This is a subaward with BioRealm from the National Institute on Alcohol Abuse and Alcoholism.


9/1/18 - 8/31/20


National Institute of Alcohol Abuse and Alcoholism (NIAAA)